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ABSTRACT 
The proliferation of the malaria-causing parasite Plasmodium falciparum within the 
erythrocyte is concomitant with massive phosphatidylcholine and phosphatidylethanolamine 
biosynthesis. Based on pharmacological and genetic data, de novo biosynthesis pathways of 
both phospholipids appear essential for parasite survival. The present study characterizes P. 
falciparum choline kinase (PfCK) and ethanolamine kinase (PfEK), which catalyse the first 
enzymatic steps of these essential metabolic pathways. Recombinant PfCK and PfEK were 
expressed as His-tagged fusion proteins from over-expressing E. coli strains, then purified to 
homogeneity and characterized. Using mice-polyclonal antibodies against recombinant 
kinases, PfCK and PfEK were shown to be localized within the parasite cytoplasm. Protein 
expression levels increased during erythrocytic development. PfCK and PfEK appeared 
specific to their respective substrate and followed Michaelis-Menten kinetics. The Km value 
of PfCK for choline was 135.3 ± 15.5 µM. PfCK was also able to phosphorylate ethanolamine 
with a very low affinity. PfEK was found to be an ethanolamine-specific kinase (Km = 475.7 ± 
80.2 µM for ethanolamine). The quaternary ammonium Hemicholinium-3 and an 
ethanolamine analog, 2-amino 1-butanol selectively inhibited PfCK or PfEK. In contrast, the 
bisthiazolium compound T3 designed as a choline analog and currently in clinical trials for 
antimalarial treatment, affected similarly PfCK and PfEK activities. Inhibition exerted by T3 
was competitive for both PfCK and PfEK and correlated with the impairment of cellular 
phosphatidylcholine biosynthesis. Comparative analyses of sequences and structures between 
both kinase types gave insights into their specific inhibition profiles and into the dual capacity 
of T3 to inhibit both PfCK and PfEK. 
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INTRODUCTION 
Plasmodium falciparum, the parasite of most severe forms of human malaria, requires intense 
membrane neogenesis to achieve successful growth and proliferation inside its hosts. During 
pathogenic blood development, one of the drastic changes is a six-fold increase in the content 
of phospholipids (PL) with a quasi-absence of cholesterol [1, 2]. Since PL salvage from the 
host plasma is not significant, the prodigious proliferative capacity of malaria parasite relies 
on its own biosynthetic machinery, more particularly on the synthesis of phosphatidylcholine 
(PtdCho) and phosphatidylethanolamine (PtdEtn) which represent 75 to 85% of the total 
parasitic PL content [3, 4]. Like other eukaryotic cells, Plasmodium is capable of synthesizing 
PtdCho and PtdEtn via the de novo CDP-choline and CDP-ethanolamine (Kennedy) pathways 
and a CDP-DAG dependent pathway leading to phosphatidylserine which can be 
decarboxylated into PtdEtn. In addition, a newly identified plant-like pathway involving 
serine decarboxylase and phosphoethanolamine N-methyltransferase generates additional 
PtdCho and PtdEtn in the parasite [5-7].  
Parasite-driven lipid synthesis accompanying parasite growth has been shown to be 
essential and many steps within PL metabolism offer potential targets for chemotherapy [8, 
9].  Because the intraerythrocytic parasite relies on host-imported precursors, the use of 
commercial choline (Cho) or ethanolamine (Etn) analogs identified the de novo PtdCho and 
PtdEtn metabolic pathways as vital to the parasite blood stage [9, 10]. Unquestionably, the 
most advanced approach is through the use of Cho analogs possessing one or two quaternary 
ammoniums. Indeed, we have identified Cho analogs that inhibit P. falciparum asexual blood 
stages at single digit nanomolar concentrations [11, 12]. The bisthiazolium T3 [13] is 
currently in development for severe malaria in human clinical trials. The primary mechanism 
of T3 antimalarial activity is likely via the perturbation of an organic cation transporter that 
mediates Cho entry into infected erythrocytes [14], thereby preventing the first crucial step in 
de novo PtdCho biosynthesis [13]. The development of Cho analogs as innovative antimalaria 
therapeutics proves that targeting lipid metabolism is a viable approach. 
An alternative pharmacological strategy consists in interfering with enzymatic steps in the 
essential metabolic pathways for parasite lipid formation.  In the so-called Kennedy pathway, 
Cho diverted from the host is phosphorylated by choline kinase (CK) into phosphocholine (P-
Cho) which is subsequently coupled to CTP, thus generating CDP-Cho by a CTP-
phosphocholine cytidylyltransferase (CCT). An equivalent de novo pathway exists for 
Plasmodium PtdEtn synthesis implying an ethanolamine kinase (EK) as first enzymatic step. 
In Plasmodium, the CDP-activated polar head groups are converted into the final products 
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PtdCho and PtdEtn by a common parasite choline/ethanolamine phosphotransferase (CEPT) 
[15] in presence of diacylglycerol (supp. Figure 1). Recent genetic experiments in the rodent 
malaria parasite P. berghei indicate that the genes coding for CK, CCT, CTP: 
phosphoethanolamine cytidylyltransferase (ECT) and CEPT are essential for parasite survival 
(Déchamps and Vial, personal communication), thus identifying enzymes involved in de novo 
PtdCho and PtdEtn metabolic pathways as potential targets for novel antimalaria therapy.  
This study aims at characterizing P. falciparum CK (PfCK) (EC 2.7.1.32) and EK (PfEK) 
(EC 2.7.1.82) which catalyze the first committed step for de novo PtdCho and PtdEtn 
synthesis, respectively, phosphorylating the plasma-originating Cho and Etn (Supp. Figure 1). 
In mammalian cells, CK is considered as the connection between PL metabolism and cell 
cycle regulation [16]. Increasing interest in CK arose from the involvement of human α-
isoform CK in cell proliferation regulation and carcinogenesis [16-18]. High levels of PtdCho 
resulting from an up-regulation of genes coding for Cho transporter and for CK correlate as a 
biochemical marker of breast cancer [19] while CKα depletion selectively kills many tumor-
derived cell lines [20-22]. Antitumoral strategy targeting this enzyme and rational drug design 
are currently actively investigated [23-27].  
P. falciparum at the blood stage likely possesses two distinct proteins for the 
phosphorylation of Cho and Etn with specificity for their natural substrate in parasite lysates 
[28] and the recombinant PfCK (PlasmoDB: PF14_0020) has been characterized in vitro [29, 
30]. A putative EK is annotated in the genome of all Plasmodium species (PlasmoDB: 
PF11_0257) (http://PlasmoDB.org) [31] but its activity has not been identified and 
characterized yet. This work identifies the activity of the gene product PF11_0257 as P. 
falciparum EK.  A comparative study of PfCK and PfEK is presented for both their cellular 
expression and their properties as recombinant proteins with the characterization of their 
substrate requirements as well as their selective inhibition. Interestingly, we found that the 
bisthiazolium T3, currently developed as a choline analog for malaria therapy, equally 
inhibited both enzymatic activities while specifically impairing parasite PtdCho biosynthesis. 
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EXPERIMENTAL 
 
Parasite culture and cDNA synthesis 
The P. falciparum 3D7 strain was maintained in A+ or O+ human red blood cells (RBC) 
(Etablissement Français du Sang, Pyrénées Méditerannée) at 5% hematocrit in RPMI 1640 
medium (Gibco) supplemented with 25 mM HEPES, 0.11 mM hypoxanthine and 0.5% (w/v) 
Albumax II (Gibco). Synchronisation of parasite cultures was performed twice at 36 hours 
interval using 5% sorbitol in phosphate buffered saline (PBS) for 5 min at 37° C during two 
parasite life cycles [32]. Infected erythrocytes were lysed by 0.1 % saponin in cold PBS at 4° 
C. After centrifugation at 1300×g for 5 min, the pellet of free parasites was washed twice with 
cold PBS. Genomic DNA was isolated from free parasites using the QIAamp® DNA Blood 
Mini kit (Qiagen) according to the manufacturer's instructions. Total RNA was extracted from 
infected RBC (IRBC) using the RNAaqueousTM kit (Ambion) and cDNA was obtained by 
RT-PCR (SuperScriptTM III First-Strand Synthesis SuperMix, Invitrogen).  
 
Cloning, Over-expression and Purification of PfCK and PfEK  
The primary sequences of the full-length PfCK (440 amino-acids) and putative PfEK (423 
amino-acids) were identified from PlasmoDB (http://PlasmoDB.org) [31]. The two ORFs 
were amplified by PCR from P. falciparum cDNA, using the high-fidelity Phusion 
polymerase with the forward primers 5’-
CAAGCTAGCATGGAAAGCAAAATCTGTGACC-3’, 5’-
CAAGCTAGCATGGAATATCAACTAAGAGAAATTGATG-3’ and the reverse primers, 
5’-CAACTCGAGATCGTCATAATCCTTGATAATATTTTTG-3’, 5’-
CAACTCGAGGTTTTTTTCCAATTTGCTCCTAAATTTTAC-3’, respectively for PfCK 
and PfEK. Restriction sites NheI and XhoI are shown in bold. PCR fragments were ligated by 
T4 DNA ligase (BioLabs) into pET24b vector, to produce pET24b-PfCK and pET24b-PfEK 
for inducible expression of C-terminal hexahistidine-tagged recombinant proteins. All 
constructs were controlled by sequencing. The plasmids were transformed into E.coli strain 
BL21(DE3)pRIL. Bacteria were grown in LB medium containing 40 µg/ml chloramphenicol 
and 50 µg/ml kanamycin at 37° C. Expression of the recombinant proteins was induced by the 
addition of 0.5 mM isopropyl β-D-thiogalactopyranose (Invitrogen). Cultures were incubated 
for 5h at 28°C. After centrifugation (15 min at 3000×g), cells were suspended in 10 ml of 
lysis buffer (25 mM Tris-HCl, pH 8.0, 2mM  β-mercapto-ethanol, 0.2 mM 
phenylmethylsulfonyl fluoride) containing one protease inhibitor cocktail tablet (Complete 
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Mini, EDTA-free, Roche). Lysis was performed by three passages through a French press 
(Thermo Spectronic), at a pressure of 1000 Pascal. Supernatants were isolated after 
centrifugation at 14000×g for 30 min at 4°C. For the first step of Plasmodium recombinant 
protein purification, the supernatant was loaded onto a 1ml HisTrap chelating column (GE 
Healthcare). After washing steps, the recombinant PfCK and PfEK were eluted with 250 mM 
imidazole. Imidazole was removed on desalting PD10 column (GE Healthcare), and the Ni-
NTA purified proteins were concentrated using Amicon Ultra-15 (Millipore) to a final volume 
~1ml. The kinases were further purified on a S75 (for PfCK) or on a S200 (for PfEK) gel 
filtration sepharose column (HiLoad Superdex, GE Healthcare) in 0.15 M NaCl, 25 mM Tris-
HCl, pH 8.0 buffer and 2 mM β-mercapto-ethanol at a flow rate of 1 ml/min. Protein 
concentrations were determined by the Bradford method [33] with bovine serum albumin 
(Pierce) as standard. Purification steps were followed by SDS - polyacrylamide gel 
electrophoresis.  
 
Circular Dichroism analysis 
Purified recombinant proteins (concentrated at 0.3 mg/ml) were used for UV-CD analysis in 
20mM sodium phosphate, pH 7.4 buffer and 2mM β-mercapto-ethanol.  CD spectra were 
recorded from 180 to 260 nm at 20° C on a Chirascan Circular Dichroism Spectrophotometer 
(Applied Photophysics Inc.) with a 0.5 cm path-length quartz cell.  Data were collected at 0.5 
nm intervals and an accumulation time of 1s. All protein spectra were measured three times 
and corrected by subtraction of respective buffer spectra. The PfCK and PfEK spectra were 
analysed with CDNN CD Spectra Deconvolution Software (Applied Photophysics). 
 
Antibody production and Western immunoblotting 
Eight-week-old female BALB/c mice (Charles River laboratories, France) were immunized 
by subcutaneous injections of 20 to 50 µg of purified recombinant PfCK or PfEK emulsified 
in Freund adjuvant and boosted every three weeks by two successive injections. For Western 
blots, IRBC were lyzed and free parasites were obtained as described in Parasite culture 
section. Parasite extracts were separated using 12% SDS-PAGE under reducing conditions 
and transferred onto a nitrocellulose membrane (Protran, Whatman). Equivalent amount of 
cells were loaded in each well (1×107 cells/well). Membranes were incubated either with pre-
immune or immune mice sera (1:500 dilution for anti-PfCK and 1:2,500 dilution for anti-
PfEK), then with horseradish peroxidase conjugated anti-mouse IgG (Promega). Signals were 
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detected by chemioluminescence (ECL Western Blotting Detection Reagents, GE 
Healthcare).  
 
Immunofluorescence assays 
IRBC fixed in 4% para-formaldehyde and permeabilized by 0.1% Triton X-100 for 10 min, 
were incubated with anti-PfCK (1:100 dilution) or anti-PfEK (1:200 dilution) antibodies 
overnight at 4° C. The presence of PfCK or PfEK was revealed by incubation with goat anti-
mouse IgG green Alexa Fluor 488 (Invitrogen) for 1 h at room temperature. Cells were plated 
on 10 well-slides then mounted on slides using a Vectashield mounting medium containing 
diamidino phenylindole (DAPI) (Vector Laboratories, Inc.). Parasites were visualized with an 
upright AxioImager-Z1 microscope equipped with an apotome and differential interference 
contrast for transmitted light (Carl Zeiss Inc.). Images were acquired using a ×63, 1.4 
apochromat oil-objective. Cropping and brightness/contrast adjustments were performed with 
Axiovision (Carl Zeiss Inc.) and ImageJ (MacBiophotonics) softwares.  
 
Kinetic parameters and inhibition assays for PfCK and PfEK 
Recombinant PfCK and PfEK were incubated with [methyl-14C] choline or [2-14C] ethan-1-ol-
2-amine with specific activity of 56 µCi/µmol or 55 µCi/µmol, respectively (Amersham 
Biosciences). The enzymatic activities were measured by the formation of radio-labeled 
phosphocholine and phosphoethanolamine. Assays were adapted from the optimization in 
Plasmodium-infected homogenates [28, 34]. Enzymatic reactions were carried out with 125 
mM Tris-HCl, pH 8.0 buffer, 10 mM ATP, 5 mM EGTA, 10 mM MgCl2 and 0.25 µCi of 
radio-labelled precursors for each assay in a final volume of 100 µl. Reactions were initiated 
with the addition of 0.5 µg of PfCK or 2 µg PfEK followed by 5 or 10 min incubation at 37°C 
for PfCK or PfEK, respectively. Reactions were stopped by heating at 96°C for 5 min. For 
each assay, a sample of 20 µl was spotted onto a thin layer chromatography (TLC) silica-gel 
plate, previously activated at 100°C for 1 h.  Radio-labelled products and substrates were then 
separated in a buffer containing ethanol/2% ammonia (1:1, v/v). Plates were exposed 
overnight to a storage phosphor screen (Molecular Biodynamics) then analyzed on a 
PhosphoImager (Storm 840, Amersham Biosciences). Radioactive spots identified by the 
migration of appropriate standards (P-Cho and P-Etn) were scraped directly into scintillation 
vials. Radioactivity was determined using a Beckman LS6500 liquid-scintillation 
spectrometer after the addition of 3ml of scintillant (Ultima Gold, Perkin Elmer).  
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For the inhibition assays, two commercial compounds, hemicholinium-3 (Sigma), 2-amino-1-
butanol (Aldrich), and a bisthiazolium compound T3 were tested. Inhibition assays were 
performed on recombinant proteins and native PfEK and PfCK from P. falciparum extracts. 
Soluble parasite extracts were obtained after saponin treatment of synchronized IRBC cultures 
at the schizont stage (1×107 parasites). Parasite pellets were washed in cold PBS and lyzed by 
sonication (Digital Sonifier, Branson Ultrasonics Corporation). The soluble fraction was 
recovered after centrifugation at 14000×g. Inhibition assays were measured by using the 
substrate concentrations at their respective affinity (Km value) and by varying the inhibitor 
concentrations. For the determination of the inhibition constant Ki of T3, different 
concentrations of inhibitor were used. Substrate or inhibitor dependent curves were analyzed 
using GraphPad Prism 4 (GraphPad software, Inc.) and were represented using the Michaelis-
Menten equation or the Lineweaver-Burk double reciprocal plots for Km, Vmax, Ki 
determination. 
 
Determination of the critical micellar concentration of T3 by light scattering 
The critical micellar concentration of T3 was determined by following the signal of dynamic 
light scattering when diluting a highly concentrated T3 solution. All the assays were carried 
out in the buffer used for the inhibition assays (Tris-HCl, pH 8 buffer). The intensity of the 
Rayleigh scattering band (R) (in kilo counts per second) was measured for each T3 
concentration. Measurements were done on a Zeta Nano Series (Malvern Instrument) and data 
processed according to the manufacturer recommendations with DTS program. The intercept 
between the two straight lines corresponded to the cmc value. 
 
Inhibition of P. falciparum phosphatidylcholine and phosphatidylethanolamine 
biosynthesis. 
The incorporations of radio-labelled [3H] -Cho (20 µM, 0.5 Ci/mmol) or [3H]-Etn (2 µM, 4.2 
Ci/mmol) into PtdCho or PtdEtn and of [3H]-hypoxanthine (1 µCi/well) into nucleic acids 
were measured on infected erythrocyte suspensions. Drug effects on P. falciparum growth 
were measured in 96 well microtiter plates filled in with 100 µl of P. falciparum IRBC 
suspension (3% final hematocrit and 5% parasitemia) and 50 µl of complete medium 
(choline-free RPMI 1640, 25mM Hepes, 10% human serum) with or without the drug. After 
30 min incubation at 37°C, 50 µl of radio-labelled precursor was added to the suspensions. 
Parasite cultures were maintained for 3 hours at 37°C, and then frozen at -80°C. After 
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thawing, the parasite macromolecules, including radioactive nucleic acids and lipids, were 
retained on glass fiber filters (Perkin Elmer) (pre-treated with 0.05% polyethylene glycol for 
Cho incorporation). Radioactivity was counted after the addition of scintillation cocktail 
(Ultima Gold, Perkin Elmer) in a liquid scintillation spectrometer. Dose-response curves were 
analyzed using GraphPad Prism 4 (GraphPad software, Inc.). The results are expressed as the 
concentration of drug resulting in 50% inhibition (IC50) of Cho, Etn or hypoxanthine 
incorporations into PC, PE or nucleic acids, respectively.  
 
RESULTS 
 
Sequence analysis of P. falciparum CK and putative EK 
The sequence alignment of the PfCK sequence with other known CKs exhibited three 
conserved motifs; (1) the ATP binding loop with the conserved residues (Ser/Thr)-Asn, (2) 
the Brenner’s phosphotransferase motif and (3) the choline/ethanolamine kinase motif (supp. 
Figure 2). We focused the analysis on residues involved in the binding of the Cho or Etn 
moiety. The Cho/Etn kinase motif consisted in a consensus sequence described by Ayoyama 
et al., 2004 [35] and redefined as follows: hhDhExxxxNxxxxDhxNhhxE (h stands for large 
hydrophobic residue). Analysis of the X-ray 3D structures of the human and C. elegans CKs 
[36]  and the mutational studies of C. elegans CK [37], indicated that three residues (Asp306, 
Gln308 and Asn311 in human CKα-2) belonging to the Brenner’s motif were also involved in 
choline binding. These three residues are conserved in CK sequences including PfCK. 
Moreover, the choline binding site consisted of a deep hydrophobic groove and an outer 
negatively charged surface as described for the human CK structure in complex with the 
phosphocholine product [36]. The hydrophobic interactions stabilizing the quaternary amine 
of choline were mediated by conserved aromatic residue (Tyr333, 354, 440 and Trp420, 423 
in hCKα-2) [36]. All five residues were found at equivalent positions in the PfCK sequence 
(supp. Figure 2). 
The P. falciparum genome database PlasmoDB [31] predicted the presence of an intronless 
gene (PF11_0257) encoding a putative EK. The alignment of the putative PfEK sequence 
with other EKs revealed the presence of the three conserved motifs already described for CKs 
(supp. Figure 2). The ATP binding loop and the Brenner’s motif of putative PfEK were highly 
similar to EK but also to CK sequences.  The consensus sequence of the Cho/Etn kinase motif 
defined above was also present in putative PfEK.  
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 10
Over-expression, purification and circular dichroism analysis of recombinant PfCK and 
PfEK 
We confirmed the coding sequence of P. falciparum EK by sequencing the cDNA of P. 
falciparum 3D7 strain (data not shown). The molecular mass of the deduced amino acid 
sequence was 49.9 kDa. DNA coding sequences of PfCK and PfEK were inserted into 
pET24b expression vector and expressed as C-terminal hexahistidine-tagged recombinant 
proteins in the E. coli strain BL21(DE3)pRIL. SDS-PAGE analysis of total proteins from 
IPTG-induced bacteria indicated the presence of prominent bands corresponding to the 
apparent molecular mass of approximately 50 and 48 kDa for PfCK and PfEK, respectively 
(supp. Figure 3A and 3B). Most of the recombinant proteins were found in the soluble 
fraction after bacterial lysis. Purification of each recombinant protein was performed first by a 
nickel-ion affinity chromatography. A further purification step using gel filtration 
chromatography yielded highly purified proteins as shown by the single detectable band on 
SDS-PAGE (supp. Figure 3C). The oligomerization states of both recombinant proteins were 
determined from the gel filtration elution profiles. The molecular mass obtained for PfCK on 
a calibrated column was ~52 kDa, indicating that the protein was monomeric in 0.15 M NaCl, 
20mM Tris, pH 8 buffer.  In contrast, under the same conditions, PfEK appeared dimeric with 
a molecular mass of ~109 kDa. Interestingly, PfCK seemed to be the only monomeric CK 
[29] while all other characterized CK and EK were dimeric [35, 38-40].  The dimer interface, 
described for human and C. elegans CK crystal structures, comprised 16 residues located at 
the C-terminal of the ATP binding loop [36, 41] (supp. Figure 2). After the two purification 
steps, both purified proteins were recovered at a final concentration of around 0.3 mg/ml for 
further studies. Average yields at the end of the purification procedure were 8-10 mg of PfEK 
and 1-2 mg of PfCK per litre of bacterial culture. Circular dichroism (CD) was used to assess 
protein folding after the purification steps. Spectra clearly exhibited two local minima and a 
maximum at 190 nm characteristic of α-helix conformation (supp. Figure 3D). For both 
proteins, the CD spectra reflected folded proteins. Secondary structure content estimation 
gave approximately 30% and 40 % α-helix for PfCK and PfEK, respectively.  
 
Cellular expression and localization of PfCK and PfEK 
We generated specific antibodies against PfCK and PfEK recombinant proteins by 
immunization of BALB-c mice. The specificity of anti-PfCK and anti-PfEK antibodies was 
verified by Western blot analysis of parasite extracts. Only one band was detected at the 
expected molecular mass for both PfCK and PfEK, while pre-immune sera did not show any 
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significant signal (Figure 1A and 1B). The antibodies were then used to detect PfCK and 
PfEK at the different stages of parasite development (ring, trophozoite and schizont stages). 
PfCK and PfEK could not be detected by Western blot at the early stage (ring) (Figure 1C and 
1D). At the trophozoite stage, anti-PfCK detected a weak band while the band detected by 
anti-PfEK was more intense (Figure 1C and 1D). At the end of the life cycle (schizont), both 
bands corresponding to PfCK and PfEK were more intense reflecting a maximal amount of 
both proteins at this stage of the P. falciparum blood development (Figure 1C and 1D). To 
localize both enzymes within the parasite, immunofluorescence analyses were carried out on 
non-synchronized parasite cultures. The signals of both anti-sera were spread throughout the 
parasite cytoplasm (Figure 2). Moreover, PfCK and PfEK were clearly detected at both 
mature stages (trophozoite and schizont) but also at the early ring stage (Figure 2), 
highlighting a greater sensitivity in the immunofluorescence assays with the anti-PfCK and 
anti-PfEK antibodies, compared to the Western blot analysis. 
 
In vitro PfCK and PfEK assays revealed two distinct enzymatic activities 
Enzymatic activities and associated kinetic parameters were determined for each purified 
recombinant protein. The assay conditions were adapted from the protocols optimized for 
extracts of P. falciparum-infected erythrocytes [28]. Enzymatic activities were measured by 
the formation of P-Cho or P-Etn from radio-labeled Cho or Etn, respectively. At the initial 
linear rate of the enzyme reactions, the activities of PfCK and PfEK were determined as 
substrate concentrations were increasing. The rate of catalysis described saturation curves 
reaching a plateau, characteristic of Michaelis-Menten kinetics for both recombinant enzyme 
activities (Figure 3). For PfCK, Lineweaver-Burk plot analysis of the enzyme activity with 
Cho yielded a Km value of 135.3 ±15.5 µM and a Vmax value of 10.7 ± 2.8 µmol/min/mg 
(Figure 3A and Table 1). For PfEK, the Km value for Etn was 475.7 ±80.2 µM, revealing a 
weaker affinity of this kinase towards its substrate compared to PfCK (Figure 3B). The 
specific activity of PfEK for ethanolamine was determined to be 1.28 ±0.11 µmol/min/mg of 
recombinant PfEK (Table 1). We evaluated the kinase selectivity by measuring their activities 
with swapped substrates. PfCK was able to catalyze the phosphorylation of Etn, but the 
affinity was drastically decreased and the catalytic activity was found to be 62.2 ± 3.5 
µmol/min/mg (approximately 6 times higher with Etn than with Cho as substrate) (Table 1 
and supp. Figure 4). In contrast, PfEK was not able to phosphorylate Cho (below a choline 
concentration to 1M). PfEK was an ethanolamine-specific kinase. 
Biochemical Journal Immediate Publication. Published on 21 Oct 2009 as manuscript BJ20091119
TH
IS
 IS
 N
O
T 
TH
E 
VE
RS
IO
N 
O
F 
RE
CO
RD
 - 
se
e 
do
i:1
0.
10
42
/B
J2
00
91
11
9
Ac
ce
pt
d M
an
u
cri
pt
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
' 2009 The Authors Journal compilation ' 2009 Portland Press Limited
 12
 
Inhibition of PfCK and PfEK by selective compounds and by the antimalarial drug T3 
 
The chemical structures of the PfCK and PfEK substrates differ by three methyl groups. 
Indeed, a quaternary ammonium in Cho replaces a primary amine in Etn. Due to the substrate-
specificity of PfCK and PfEK, selective inhibition of the enzymatic activities was 
conceivable. On the basis of chemical properties of the substrates, Hemicholinium-3 (HC-3) 
and 2-amino 1-butanol (2-AB) were used as Cho and Etn analogs, respectively (Figure 4A). 
HC-3 has been reported to be an inhibitor of choline transport [42] and CK [43-45] while 2-
AB was shown to specifically inhibit EK [28]. When added to the recombinant PfCK, HC-3 
dose-dependently inhibited the kinase activity. When Cho concentration was used at its Km 
value, HC-3 significantly inhibited PfCK from 0.1 mM, with the concentration of drug to 
inhibit half of the in vitro PfCK activity (inhibition concentration 50: IC50) of 0.58± 0.02 mM 
(Figure 4B). However, HC-3 was not able to significantly inhibit PfEK below an inhibitor 
concentration of 3 mM (Figure 4C). Inversely, the Etn analog, 2-AB selectively inhibited 
PfEK activity with IC50 value of 1.36± 0.17 mM but had no significant effect on PfCK 
activity at this inhibitor concentration (IC50 value above 10 mM) (Figure 4B and 4C).  
The bisthiazolium T3 (Figure 4A), designed as a Cho analog to target the PtdCho synthesis 
pathway [13, 46], was similarly assessed on the activity of both recombinant enzymes. T3 
affected the activity of PfCK through an inhibition effect reflected by an IC50 value of 1.12± 
0.11 mM (Figure 4B). Remarkably, T3 dose-dependently inhibited the PfEK activity at 
concentrations similar to those inhibiting PfCK as evidenced by an IC50 value of 0.61± 0.02 
mM (Figure 4C). While the substrate analogs of CK and EK activities selectively inhibited the 
recombinant PfCK and PfEK, T3 was able to equally inhibit PfCK and PfEK with comparable 
efficiency.  
In addition, we investigated inhibitory properties of the compounds on P. falciparum 
endogenous PfCK and PfEK activities. 2-AB and HC-3 also selectively inhibited PfEK and 
PfCK activities, with respective IC50 of 0.46± 0.03 mM and 0.22± 0.01 mM (supp. Figure 5). 
The bis-thiazolium T3 inhibited both cellular activities within the same concentration range 
with IC50 of 0.79± 0.05 mM and 0.52± 0.03 mM, respectively (supp. Figure 5). T3 similarly 
inhibited recombinant and endogenous kinase activities as proved by comparable IC50 values. 
Thus, the inhibition specificities of 2-AB and HC-3 and the ability of T3 to inhibit both 
kinases were found on recombinant and endogenous EK and CK activities. 
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In order to elucidate the mode of action of T3, activity assays with increasing concentrations 
of drug were carried out on both recombinant PfCK and PfEK. Increasing concentrations of 
inhibitor augmented the slope of the primary plots (1/v=f(1/S)) and all lines intersect on the 
(1/v) axis (Figure 5A and 5B). T3 acted as a competitive inhibitor of Cho and Etn substrates. 
The Ki values of T3, calculated from Lineweaver-Burk linearization and the plot of the 
apparent Km as a function of the inhibitor concentration, were found to be 1.03 mM for PfCK 
and 0.73 mM for PfEK (Figure 5A and 5B). These values indicated that T3 exerts a 
competitive inhibitory effect with similar affinity for both PfCK and PfEK. The Dixon plot of 
the reciprocal of velocity vs inhibitor concentration is also a convenient way of calculating the 
inhibition constant. Using this graph (not shown), we found comparable Ki values of T3 (0.9 
and 0.7 mM for PfCK and PfEK, respectively) as those obtained from Lineweaver-Burk 
linearization. Taken together, these results indicated a competitive inhibition of T3 for both 
kinase reactions with Ki values in the same range as the IC50 values and an inhibitory effect of 
T3 affecting PfCK and PfEK activities with similar affinity. 
As shown in figure 4A, T3 has two positively charged head groups linked by a hydrophobic 
hydrocarbon chain, properties resembling those of a cationic detergent. Although, T3 exerted 
a competitive inhibition on PfCK and PfEK activities, we wanted to exclude that T3 could 
affect the proteins in a detergent like manner. Thus, we determined the critical micellar 
concentration (cmc) value of T3 by dynamic light scattering. The measurements of the 
Rayleigh scattering band intensities (R) for various T3 concentrations were performed (supp. 
Figure 6). For low T3 concentrations, the intensity of the scattered light followed a linear 
correlation resulting from the presence of monomers in the solution. As the concentration of 
T3 increased, the equilibrium between the monomer and the micelle forms of T3 was reached 
as deduced from the abrupt increase of light intensity at the cmc. The cmc value of T3 was 
found to be at 200 mM in the buffer used for inhibition assays (Tris-HCl, pH 8) (supp. Figure 
6). This value was far above the IC50 values of T3 found to inhibit PfCK and PfEK, excluding 
a detergent-like effect of the drug as the mechanism for the observed inhibition. 
 
Effects of compounds on cellular phosphatidylcholine and phosphatidylethanolamine 
biosynthesis 
We monitored newly synthesized PtdCho and PtdEtn of P. falciparum infected erythrocytes 
by measuring the incorporation rate of radio-labeled precursors. P. falciparum cultures were 
treated with the three compounds HC-3, AB-2 and T3. To detect unspecific effects, the 
incorporation of radio-labeled hypoxanthine into DNA was simultaneously evaluated. The 
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concentrations required to inhibit 50% of the DNA synthesis were found to be 74± 5 µM for 
T3 and above 2 mM for HC-3 and 2-AB.  
HC-3 had a complete inhibitory effect on the Cho incorporation into cellular PtdCho with an 
IC50 value (concentration required to inhibit 50% of PtdCho synthesis) of 79± 9 µM (supp. 
Figure 7A). At this concentration, neither PtdEtn nor the DNA synthesis were yet altered 
(supp. Figure 7A). The production of PtdEtn was selectively decreased by AB-2 treatment 
(IC50 = 40± 4 µM) while this Etn analog did not affect PtdCho biosynthesis even when 
significantly higher concentrations were used (> 1 mM) (supp. Figure 7B). Thus, HC-3 and 
AB-2 exerted a selective effect on the de novo CDP-Cho and CDP-Etn biosynthesis pathways, 
respectively. When T3 was added to infected erythrocytes, the incorporation of Cho was 
impaired (IC50 = 12±3 µM) at concentrations that did not perturb DNA synthesis. In contrast, 
a decrease in PtdEtn synthesis was only observed at higher T3 concentrations that also 
affected hypoxanthine incorporation (supp. Figure 7C). Thus, the antimalarial effect of T3 is 
likely related to a decrease of parasite PtdCho but not PtdEtn synthesis.  
 
DISCUSSION 
This study provided evidence that the P. falciparum gene PF011_0257 coded for an 
ethanolamine kinase activity. We also showed that PfEK and PfCK were selective for their 
respective substrate, Etn and Cho. The catalysis of PfCK toward the phosphorylation of Etn 
was probably of no physiological significance since both metabolic pathways appeared 
essential in P. berghei parasite indicating that one enzyme cannot be substituted to the other. 
The levels of both kinases increased within the cytoplasm along the parasite life cycle. This 
suggests that PfCK and PfEK could be dedicated to their own pathways, thereby increasing 
the possibilities for regulation processes.  
As the Cho/Etn kinase motif did not exhibit any significant difference by comparing CK and 
EK sequences, we surmised that the specificity of these kinases resided elsewhere. 
Interestingly, the glutamine residue (Q290 for PfCK and Q308 for hCKα-2) within the 
Brenner’s motif, was conserved amongst the CKs while this position was occupied by a 
hydrophobic amino acid in EK sequences (supp. Figure 2). Ethanolamine-specific kinases 
lacked one of the five aromatic residues forming the hydrophobic pocket for the stabilization 
of the Cho quaternary amine (Y329 for PfCK and Y354 for hCKα-2) [36]. Indeed, most CKs 
contained an insertion encompassing the Tyr329 located at the C-terminal end of the Cho/Etn 
motif (supp. Figure 2), which was not found in ethanolamine-specific kinases. Thus, within 
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the residues involved in the binding of the polar head substrate, CK sequences differed from 
EK sequences by the substitution of the pivotal polar residue of the Brenner’s motif with a 
hydrophobic residue (Gln290 -> Leu298 for PfCK and PfEK) and by an insertion at the C-
terminal of the Cho/Etn kinase motif of CKs. These observations were corroborated by the 
analysis of S. cerevisiae EK. This enzyme exhibited a polar residue (glutamine) where a 
hydrophobic residue is usually found (Leu298 for PfEK). Moreover, S. cerevisiae EK 
sequence also contained the insertion at the C-terminal of the Cho/Etn kinase motif defined 
above as CK specific. To our knowledge, ScEK is the only EK presenting significant Cho 
phosphorylation activity in vitro [16, 35, 39, 47, 48].  
 
Since PfCK and PfEK discriminate their respective substrate containing a quaternary 
ammonium or a primary amine, selective inhibition by appropriate analogs is conceivable. 
The experiments reported here demonstrate that recombinant as well as endogenous PfCK and 
PfEK are selectively inhibited by two substrate analogs, HC-3 and 2-AB, respectively. 
Surprisingly, the antiphospholipid effector T3 designed as a Cho analog had an effect, not 
only on PfCK activity but also on PfEK activity. In order to obtain insights into the different 
inhibition profiles of HC-3 and 2-AB on one side and into the similar affinity of the bis-
thiazolium for both enzymes on the other side, we carried out a combined analysis of 
sequence alignments and of kinase crystal structures. As we did for the comparison of CK and 
EK sequences (see above and supp. Figure 2), we exploited the 3D crystal structures of PfCK 
and P. vivax EK (PfEK structure being not available) recently solved by a structural genomics 
consortium. Although both kinase types share the same overall fold, an interesting difference 
appeared when both structures were superimposed. Indeed, the PfCK crystal structure showed 
that the insertion comprising the tyrosine residue at the C-terminal of the Cho/Etn kinase 
motif was located near the catalytic site (Figure 6). As was evident in the primary sequence 
alignment, this insertion was absent in EK sequences. Additionally, the human CK crystal 
structure in complex with HC-3 revealed that one aromatic ring of HC-3 stacked onto the 
tyrosine ring residue of the insertion (Y354 for hCKα-2) (Figure 6). This CK-specific 
interaction could be indispensable to discriminate between the inhibitors and thus the 
substrates, whereas the absence of the insertion in PfEK preventing any Tyr-mediated 
interaction would be detrimental for HC-3 or Cho binding. Similar affinities of T3 for both 
enzymes were observed. It is likely that the conformation of the thiazolium head group being 
planar contrary to Cho and HC-3 quarternary ammonium, allows its entry into the PfEK 
catalytic site. Additionally, the flexibility due to the 12-carbon atom linker between both 
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thiazolium groups, could allow quaternary ammonia (or just one ammonium) to adapt to 
PfCK and PfEK catalytic sites.  
More investigations are needed to explain the dual potentiality of T3 on both PfCK and PfEK 
activities. Since both metabolic pathways are essential, PfCK and PfEK appear crucial for the 
P. falciparum survival. In the parasite, T3 selectively impaired PtdCho biosynthesis that likely 
explains its antimalarial effect while PtdEtn biosynthesis did not appear to be primarily 
affected. As mentioned above, the primary action of T3 is likely to prevent Cho entry into the 
parasites by blocking an organic cation transporter. Nevertheless, the inhibition of two 
Plasmodium enzymes at similar levels opens the way to the design of new scaffolds toward 
dual molecules. The ability to affect more than one target for antimalarial therapy is precious 
to delay the emergence of resistant malaria strains, which is currently a crucial issue in the 
battle against malaria. 3D crystal structures of complexes between these both enzymes and T3 
should provide the atomic details of the interactions, necessary for future structure-based drug 
design of novel analogs.  
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TABLE: 
 
Table 1: Kinetic values for recombinant PfCK and PfEK. 
Enzyme 
Substrate 
Km (µM) 
 
Vmax (µmol/min/mg) 
PfCK 
choline 
ethanolamine 
 
 
135.3 ±15.5 
>500 mM 
 
 
10.76 ±2.81 
62.20 ±3.55 
 
PfEK 
ethanolamine  
choline 
 
457.7 ±80.2  
NA 
 
1.28 ±0.11  
NA 
NA for non applicable 
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FIGURE LEGENDS: 
 
Figure 1: Western immunoblot of PfCK and PfEK 
Western blots were revealed with anti-PfCK (A, C) and anti-PfEK (B, D). For A and B: Lane 
1, immune serum on non-infected erythrocytes; Lane 2, immune serum on P. falciparum 
lysate; Lane 3, pre-immune serum on P. falciparum lysate.  
For C and D panels, Western blots were revealed at the three parasite stage development (R: 
ring; T, trophozoite; S: schizont). Parasite cultures were synchronized and an equal quantity 
of parasites (107 cells) was treated for each stages. 
 
Figure 2: PfCK and PfEK localization  
Immunofluorescence assays were done on human red blood cells infected by P. falciparum 
3D7 strain and revealed by anti-PfCK (A) or anti-PfEK (B) (green). Nuclei were stained in 
blue with DAPI. Differential interference contrast (DIC) images and merges were presented. 
Three representative parasitic stages were shown: ring, mature trophozoite and schizont. 
 
Figure 3: Kinetic parameters of PfCK and PfEK 
Activity was measured by the formation of phosphocholine or phosphoethanolamine with 
increasing substrate concentrations (see Experimental section). Experiments have been done 
four times for PfCK and three times for PfEK, each time in duplicate. Representative 
Michaelis-Menten and Lineweaver-Burk linearization (inserts) plots are shown for PfCK (A), 
and PfEK (B) enzymes. Activity was expressed as µmol/min/mg. Data were presented as 
mean ±standard deviation from three measurements. 
 
Figure 4: Inhibition of recombinant PfCK and PfEK 
(A) Chemical structures of two commercial compounds, Hemicholinium-3 and 2-amino-1 
butanol known to inhibit CK and EK, respectively and of T3 which belongs to the second 
generation of bis-quaternary ammonium salt. The chemical structure of T3 is a duplicated bis-
thiazolium separated by a 12-carbon atom aliphatic chain. This compound is currently under 
human clinical trials. (B, C) Inhibition curves of PfCK and PfEK. Activities of PfCK (B) and 
PfEK (C) were measured with increasing concentrations of both specific inhibitors HC-3(∆), 
2-AB(○) and of T3 (■). Activity of both enzymes was giving in percentage of controls. Data 
are presented as mean ±standard deviation from three measurements. The inhibitor 
concentrations at 50% activity corresponded to the IC50 values (dotted lines). 
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Figure 5: Inhibition kinetic of PfCK (A) and PfEK (B) by T3 compound 
On the left panels, Lineweaver-Burk plots were shown at increasing drug concentrations ; (A) 
inhibition of PfCK with 0 (∆), 0.5 (○) and 1 mM (▲) T3 ; (B) inhibition of PfEK 0 (∆), 0.25 
(□) and 0.5 (○) mM T3. Experiments were done twice in triplicate. Data are presented as 
mean ±standard deviation from three measurements. 
On the right panels, (A) for PfCK and (B) for PfEK, the apparent Km (Km’) were plotted as 
function of the inhibitor concentration, Ki values were obtained by the value at the intercept 
with the x-axis as indicated by the arrow (-Ki).  
 
Figure 6: Comparison of PfCK and P. vivax EK crystal structures  
Superimposition of the Brenner’s and Cho/Etn kinase motifs of PfCK (black) and P. vivax EK 
(grey) crystal structures. The insertion containing the tyrosine 329 is not present in PvEK 
structure. Side-chains of Gln290 (PfCK) and Leu298 (PvEK) residues conserved amongst CK 
and EK, respectively, are indicated. The position of HC-3 (white) was obtained by the 
superimposition of the hCKα-2 structure in complex with HC-3. Only HC-3 was let visible. 
The model suggested that the tyrosine 329 of PfCK (equivalent to Tyr354 in hCKα-2) could 
interact with HC-3 aromatic ring. The PDB files used were 3FI8 for PfCK, 2QG7 for PvEK 
and 3FI2 for the hCKα-2 – HC-3 complex. This figure has been done with PyMol software. 
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Figure 1 
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Figure 2 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
 
 
288
377280
Y329
Q290
L298
340
Biochemical Journal Immediate Publication. Published on 21 Oct 2009 as manuscript BJ20091119
TH
IS
 IS
 N
O
T 
TH
E 
VE
RS
IO
N 
O
F 
RE
CO
RD
 - 
se
e 
do
i:1
0.
10
42
/B
J2
00
91
11
9
Ac
ce
pte
d M
an
us
cri
pt
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
' 2009 The Authors Journal compilation ' 2009 Portland Press Limited
